Section Arrow
ACET.NASDAQ
- Adicet Bio
Quotes are at least 15-min delayed:2024/04/29 17:44 EDT
Last
 1.59
-0.09 (-5.36%)
Day High 
1.765 
Prev. Close
1.68 
1-M High
2.43 
Volume 
1.61M 
Bid
1.59
Ask
1.61
Day Low
1.59 
Open
1.7 
1-M Low
1.66 
Market Cap 
138.04M 
Currency USD 
P/E -- 
%Yield 5.35 
10-SMA 2.01 
20-SMA 2.13 
50-SMA 2.27 
52-W High 7.5 
52-W Low 1.1 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.31/-2.46
Enterprise Value
155.75M
Balance Sheet
Book Value Per Share
2.07
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
DNAGinkgo Bioworks Holdings0.9898+0.1297+15.08%-- 
JAGXJaguar Health0.208+0.028+15.56%-- 
IBRXImmunityBio8.99+1.64+22.31%-- 
GERNGeron Corp4.14+0.35+9.23%-- 
XFORX4 Pharmaceuticals1.09-0.075-6.44%-- 
Quotes are at least 15-min delayed:2024/04/29 17:44 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate,ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.